In light of recent findings, would you consider prescribing dutasteride to men with low-risk prostate cancer to reduce their risk of PCa progression?

Share this article:

A randomized, double-blind study published recently in The Lancet showed that men on active surveillance for low-risk prostate cancer (PCa) who received the 5α-reductase inhibitor dutasteride for three years had a significant 38% decreased risk of PCa progression compared with men who took placebo. The investigators concluded that their findings “show that dutasteride could be a beneficial adjunct to active surveillance for men with low-risk prostate cancer, delaying their time to pathological progression and initiation of primary therapy.”

Renal & Urology News would like to ask its urologist readers the following question.


Leave a comment below to explain your choice.
Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

How much influence does the U.S. Surgeon General have on the nation's public health?

How much influence does the U.S. Surgeon General ...

The U.S. Surgeon General is the operational head of about 6,800 uniformed health officers.

During your career, have you ever rendered in-flight medical assistance?

During your career, have you ever rendered in-flight ...

It is inevitable that some passengers will become ill during a flight.

How do you feel about on-call emergency department coverage?

How do you feel about on-call emergency department ...

The nation's community hospitals are facing increasing problems obtaining emergency on-call coverage.